The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global specialty generics market reached a value of US$ 57.3 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 11.1% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Specialty generics are generic versions of specialty drugs, once they get off-patent. These drugs are used to treat chronic or complex health conditions including cancer, autoimmune diseases, epilepsy, HIV, Hepatitis, multiple sclerosis, rheumatoid arthritis, etc. Speciality generics are cost-effective as compared to their branded versions as they don’t require costly development and marketing costs.
Compared to traditional generics, the speciality generics market is more concentrated with fewer players due to their complex manufacturing requirements, higher capital costs and relatively lower volumes as a result of smaller patient population. This results in lower price reduction compared to the branded drug and consequently higher margins compared to traditional generics. Speciality generics require special handling, administration, monitoring and generally need prior authorization to order them. The global speciality generics market is currently being driven by several factors such as rising ageing population, patent expiration of a number of branded specialty drugs, increasing prevalence of various life-threatening diseases such as cancer, multiple sclerosis, HIV, etc., cost containment measures from healthcare providers, growth from emerging markets, etc.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global specialty generics market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on route of administration, indication and distribution channel.
Breakup by Region:
Breakup by Route of Administration:
Breakup by Indication:
Breakup by Distribution channel:
The global specialty generics market consists of numerous manufacturers. Some of the leading players operating in the market are Teva Pharmaceuticals Industries, Akorn, Inc., Mylan N.V., Mallinckrodt, Sandoz International GmbH, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Valeant Pharmaceuticals, Apotex Corp., Endo International plc.
IMARC Group’s latest report provides a deep insight into the global specialty generics market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the specialty generics market in any manner.
|Base Year of the Analysis||2020|
|Segment Coverage||Route of Administration, Indication, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, China, Japan, India, South Korea, Brazil, Mexico|
|Companies Covered||Teva Pharmaceuticals Industries, Akorn, Inc., Mylan N.V., Mallinckrodt, Sandoz International GmbH, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Valeant Pharmaceuticals, Apotex Corp. and Endo International plc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global specialty generics market was valued at US$ 57.3 Billion in 2020.
The increasing prevalence of numerous life-threatening diseases, such as cancer, multiple sclerosis, HIV, etc., is primarily catalyzing the global specialty generics market.
Sudden outbreak of the COVID-19 pandemic had led to the implementation of stringent lockdown regulations across several nations resulting in delayed R&D activities pertaining to specialty generics.
Based on the route of administration, the global specialty generics market can be segregated into injectables, oral, and others. Among these, injectables hold the majority of the total market share.
Based on the indication, the global specialty generics market has been bifurcated into oncology, autoimmune diseases, infectious diseases, and others. Currently, oncology diseases exhibit a clear dominance in the market.
Based on the distribution channel, the global specialty generics market can be categorized into retail pharmacies, specialty pharmacies, and hospital pharmacies. Among these, specialty pharmacies currently account for the majority of the total market share.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.
Some of the major players in the global specialty generics market include Teva Pharmaceuticals Industries, Akorn, Inc., Mylan N.V., Mallinckrodt, Sandoz International GmbH, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Valeant Pharmaceuticals, Apotex Corp., Endo International plc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at